Design, synthesis and in vitro testing of 7-methoxytacrine-amantadine analogues: A novel cholinesterase inhibitors for the treatment of Alzheimer's disease

Medicinal Chemistry Research

Volumn 24, Issue 6, 2015, Pages 2645-2655

  Spilovska, Katarina ^a,b,e   Korabecny, Jan ^a,b,c,e   Horova, Anna ^a   Musilek, Kamil ^b,d   Nepovimova, Eugenie ^a,b   Drtinova, Lucie ^a   Gazova, Zuzana ^d   Siposova, Katarina ^d   Dolezal, Rafael ^b,c   Jun, Daniel ^a,b   Kuca, Kamil ^b,c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^d INSTITUTE OF EXPERIMENTAL PHYSICS   (Slovakia)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

7 MEOTA; Acetylcholinesterase; Alzheimer's disease; Amantadine; Butyrylcholinesterase; Inhibitor

Indexed keywords

7 METHOXYTACRINE; 7 METHOXYTACRINE AMANTADINE THIOUREA; 7 METHOXYTACRINE AMANTADINE UREA; ACETYLCHOLINESTERASE; AMANTADINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HETERODIMER; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CARBON NUCLEAR MAGNETIC RESONANCE; CHOLINESTERASE INHIBITION; DEMENTIA; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84930931326     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-015-1316-x     Document Type: Article

References (53)

1. Bartolini M, Bertuci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V (2007) Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. ChemBioChem 8(17):2152-2161
2. Bielavsky J (1977) Analogues of 9-amino-1,2,3,4-tetrahydroacridine. Collect Czechoslov Chem Commun 42(9):2802-2808
3. Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312-3322
4. Bormann J (1989) Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur J Pharmacol 166(3):591-592
5. Caumont AS, Octave JN (2006) Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett 394(3):196-201
6. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target- directed ligands to combat neurodegenerative diseases. J Med Chem 51(3):347-372
7. Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev 35(6):1397-1409
8. Cummings JL (2004) Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis 1(2):60-69
9. Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4(2):131-138
10. Dejmek L (1990) 7-MEOTA. Drugs Future 15:126-129
11. Ellman GL, Courtney KD, Andres V, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
12. Forest Pharmaceuticals Inc (2003) Namenda package insert. Forest Pharmaceuticals Inc., St. Louis
13. Gauthier S, Poirier J (2008) Current and future management of Alzheimer's disease. Alzheimers Dement 4(1 Suppl 1):S48-S50
14. Giacobini E (2004) Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50(4):433-440
15. Greig NH, Utsuki T, Yu QS, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK (2001) A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17(3):159-165
16. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K, Sambamurti K, Brossi A, Lahiri DK (2005) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lower Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 102(47):17213-17218
17. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL (1993) Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 90(19):9031-9035
18. Jahn H (2013) Memory loss in Alzheimer's disease. Dialogues Clin Neurosci 15(4):445-454
19. Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Pohanka M, Opletalova V, Dohnal V, Kuca K (2010) Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer's disease. Bioorg Med Chem Lett 20(20):6093-6095
20. Korabecny J, Musilek K, Zemek F, Horova A, Holas O, Nepovimova E, Opletalova V, Hroudova J, Fisar Z, Jung YS, Kuca K (2011) Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine - new tacrine derivate with cholinergic properties. Bioorg Med Chem Lett 21(21):6563-6566
21. Korabecny J, Dolezal R, Cabelova P, Horova A, Hruba E, Ricny J, Sedlacek L, Nepovimova E, Spilovska K, Andrs M, Musilek K, Opletalova V, Sepsova V, Ripova D, Kuca K (2014) 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: synthesis, pharmacological evaluation, molecular modeling and QSAR studies. Eur J Med Chem 82:426-438
22. Kotermanski SE, Johnson JW (2009) Mg2 + imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci 29(9):2774-2779
23. Krall WJ, Sramek JJ (1999) Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33(4):441-450
24. Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, Silman I, Sussman JL (2000) Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystalogr 56(Pt 11):1385-1394
25. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS (2003) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4(2):97-112
26. Lipinski CA, Lombardo FM, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Drug Deliv Rev 46(1-3):3-26
27. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5(2):160-170
28. Magazanik LG, Antonov SM, Lukomskaya NY, Potapeva NN, Gmiro VE, Johnson J (1996) Blockade of glutamate- and cholinergic ion channels by amantadane derivatives. Neurosci Behav Physiol 26(1):13-22
29. Manning SM, Boll G, Fitzgerald E, Selip DB, Volpe JJ, Jensen FE (2011) The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain. Int J Dev Neurosci 29(7):767-773
30. Marx JL (1987) Alzheimer's drug trial put on hold. Science 238(4830):1041-1042
31. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81-104
32. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDock Tools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785-2791
33. Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Mannisto PT, Hong JS (2011) Amantadine protects dopamine neurons by a dual action: reducing activation microglia and inducing expression of GDNF in astroglia. Neuropharmacology 61(4):574-582
34. Page G, Peeters M, Maloteaux JM, Hermans E (2000) Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine. Eur J Pharmacol 403(1-2):75-80
35. Patocka J, Jun D, Kuca K (2008) Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab 9(4):332-335
36. Peeters M, Page G, Maloteaux JM, Hermans E (2002) Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res 949(1-2):32-41
37. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612
38. Pohanka M, Jun D, Kuca K (2008) Improvement of acetylcholinesterase-based assay for organophosphates in was of identification by reactivators. Talanta 77(1):451-454
39. Rizzo S, Bisi A, Bartolini M, Mancini F, Belluti F, Gobbi S, Andrisano V, Rampa A (2011) Multi-target strategy to address Alzheimer's disease: design, synthesis and biological evaluation of new tacrine-based dimers. Eur J Med Chem 46(9):4336-4343
40. Schmitt HP (2005) On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses 65(2):259-265
41. Silman I, Sussman JL (2005) Acetylcholinesterase: "classical" and "non-classical" functions and pharmacology. Curr Opin Pharmacol 5(3):293-302
42. Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, Tarozzo G, Reggiani A, Martini C, Piomelli D, Melchiorre C, Rosini M, Cavalli A (2012) Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 55(22):9708-9721
43. Soukup O, Jun D, Zdarova-Karasova J, Patocka J, Musilek K, Korabecny J, Krusek J, Kaniakova M, Sepsova V, Mandikova J, Trejtnar F, Pohanka M, Drtinova L, Pavlik M, Tobin G, Kuca K (2013) A resurrection of 7-MEOTA: a comparison with tacrine. Curr Alzheimer Res 10(8):893-906
44. Spilovska K, Korabecny J, Kral J, Horova A, Musilek K, Soukup O, Drtinova L, Gazova Z, Siposova K, Kuca K (2013) 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment - synthesis, biological evaluation and molecular modeling studies. Molecules 18(2):2397-2418
45. Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A (1989) Long-term hepatotoxicity of tacrine. Lancet 1(8640):729
46. Tayeb HO, Yang HD, Price BH, Tarazi FI (2012) Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 134(1):8-25
47. The PyMol Molecular Graphics System. http://www.pymol.org
48. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N (1996) Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271(12):6839-6844
49. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455-461
50. Yan A, Wang K (2012) Quantitative structure and bioactivity relationship study on human acetylcholinesterase inhibitors. Bioorg Med Chem Lett 22(9):3336-3342
51. Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 6(1):19-33
52. Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, Kuca K (2014) Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 13(6):759-774
53. Zheng H, Fridkin M, Youdim M (2014) From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals 7(2):113-135